|
|
|
|
|
|
|
|
|
|
Gynecologic Oncology Case Reports - Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation
Highlights
►
Nintedanib is an anti-angiogenic agent that has demonstrated activity
in relapsed ovarian cancer
► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery six years after her diagnosis
► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer
► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery six years after her diagnosis
► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.